Schornstein Amends Stake in Assembly Biosciences

TL;DR

Schornstein filed a 13D/A for Assembly Biosciences, Inc. - check for changes in stake.

AI Summary

Alexander Schornstein filed an amendment (Amendment No. 3) to Schedule 13D on June 24, 2024, regarding Assembly Biosciences, Inc. The filing indicates a change in the reporting person's holdings or intentions concerning the company's common stock. Schornstein is located in Aachen, Germany.

Why It Matters

This amendment signals a potential shift in significant shareholder activity for Assembly Biosciences, Inc., which could influence stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant changes in ownership or strategy by major shareholders, which can introduce volatility.

Key Players & Entities

• Alexander Schornstein (person) — Reporting Person
• Assembly Biosciences, Inc. (company) — Issuer
• 0001079973-24-000954 (filing_id) — Accession Number
• June 24, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) (CUS

Filing Documents

• schornstein_13da.htm (SC 13D/A) — 44KB
• 0001079973-24-000954.txt ( ) — 45KB

Security and Issuer

Item 1. Security and Issuer This Schedule 13D (the “ Schedule 13D ”) relates to the common stock, par value $0.001 per share (the “ Common Stock ”), of Assembly Biosciences, Inc., a Delaware corporation (the “ Issuer ”). The Issuer’s principal executive offices are located at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, California 94080. Item 2. Identity and Background (a) This Schedule 13D is being filed by Alexander Schornstein (“ Schornstein ” or the “ Reporting Person ”). (b) The principal place of business and office for the Reporting Person is located at Kaiser-Friedrich-Allee 2, 52074 Aachen, Germany. (c) The Reporting Person is self-employed as an entrepreneur and investor. (d) — (e) During the last five years, the Reporting Person has not been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) The Reporting Person is a citizen of the Federal Republic of Germany. Item 3. Source and Amount of Funds or Other Consideration On or about October 17, 2023, the Reporting Person purchased shares of the Issuer from the open market, resulting in the Reporting Person becoming a 5% shareholder of the Issuer. On or about October 23, 2023, the Reporting Person purchased shares of the Issuer from the open market, resulting in the Reporting Person becoming a 10% shareholder of the Issuer. On or about the period from November 20 to November 21, 2023, the Reporting Person purchased shares of the Issuer from the open market, resulting in the Reporting Person becoming an 11.51% shar

View Full Filing

View this SC 13D/A filing on SEC EDGAR